William Haskel - Paratek Pharmaceuticals President
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
President
Mr. William M. Haskel is Senior Vice President, Chief Compliance Officer, General Counsel of the Company. From 2011 until March 2015, Mr. Haskel served as the Senior Vice President, General Counsel, Chief Compliance Officer and Corporationrationrate Secretary at Cambrex Corporationrationration, where he reported to the CEO, and was a member of core management committees. In his role at Cambrex Corporationrationration, Mr. Haskel provided counsel to the board of directors, CEO, and senior management, and was responsible for the global law function as well as overseeing Global Regulatory and Quality Affairs, and Environment, Health and Safety and was a principal adviser for Board, Governance, MA, Securities and Corporationrationrate matters. Previously, Mr. Haskel enjoyed an 18year career of progressive responsibilities at Wyeth, which was acquired by Pfizer in 2009 in a transaction valued at 68 billion. Mr. Haskel served as Vice President and Associate General CounselCorporationrate where he was an advisor to executive management and managed a group of 33 employees19 lawyers across corporate and pharmaceutical division headquarters and led legal teams on a series of complex multibillion dollar global transactions that drove the Company transition from a diversified holding company to a focused health care company since 2015.
| Age | 61 |
| Tenure | 9 years |
| Phone | 617 807 6600 |
| Web | https://paratekpharma.com |
Paratek Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Paratek Pharmaceuticals currently holds 258.41 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Paratek Pharmaceuticals has a current ratio of 3.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Paratek Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 3 records | PRESIDENT Age | ||
| William Jones | Corvus Pharmaceuticals | 58 | |
| Erik Verner | Corvus Pharmaceuticals | 59 | |
| Bruce CFA | Equillium | 58 | |
Management Performance
| Return On Asset | -0.18 |
Paratek Pharmaceuticals Leadership Team
Elected by the shareholders, the Paratek Pharmaceuticals' board of directors comprises two types of representatives: Paratek Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paratek. The board's role is to monitor Paratek Pharmaceuticals' management team and ensure that shareholders' interests are well served. Paratek Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paratek Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Ex Chairman | ||
| FACC FAHA, CEO Director | ||
| Karen McGrath, VP HR | ||
| Sarah Higgins, Interim Principal Financial Officer and Principal Accounting Officer | ||
| Ben Strain, VP CEO | ||
| William Haskel, Senior Vice President General Counsel, Corporate Secretary | ||
| Adam Woodrow, Vice President and Chief Commercial Officer | ||
| Jason Burdette, VP Operations | ||
| Randall Brenner, Chief Officer |
Paratek Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paratek Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |